Jianquan Yang

Jianquan Yang

Auto-generated profile, based on publicly available information

Jianquan Yang

Department of Radiology, University of Colorado Denver, Aurora, CO 80045, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JYJianquan Yang
Jianquan Yang
JXJingli Xu
Jingli Xu
RGRene Gonzalez
Rene Gonzalez
TLThomas Lindner
Thomas Lindner
CKClemens Kratochwil
Clemens Kratochwil
YMYubin Miao
Yubin Miao
68 Ga-DOTA-GGNle-CycMSH hex , a radiolabeled melanocortin-1 receptor–targeting imaging probe, detects melanoma in first-in-human testing.

11 February 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
HGHaixun Guo
Haixun Guo
JYJianquan Yang
Jianquan Yang
FGFabio Gallazzi
Fabio Gallazzi
YMYubin Miao
Yubin Miao
The purpose of this study was to examine the profound effect of the ring size of the radiolabeled lactam bridge–cyclized α-melanocyte–stimulating hormone (α-MSH) peptide on its melanoma-targeting properties. Methods: A novel cyclic α-MSH peptide, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Nle-c[Asp-His-d-Phe-Arg-Trp-Lys]-CONH2 (DOTA-Nle-CycMSHhex), was synthesized and radiolabeled with 111In. The melanocortin-1 receptor–binding affinity of DOTA-Nle-CycMSHhex was determined in B16/F1 melanoma cells. The internalization and efflux of 111In-DOTA-Nle-CycMSHhex were examined in B16/F1 cells. The melanoma-targeting properties and SPECT/CT characteristics of 111In-DOTA-Nle-CycMSHhex were determined in B16/F1 melanoma–bearing C57 mice. Results: DOTA-Nle-CycMSHhex displayed 1.77 nM receptor-binding affinity. 111In-DOTA-Nle-CycMSHhex exhibited rapid internalization and extended retention in B16/F1 cells. The tumor uptake of 111In-DOTA-Nle-CycMSHhex was 24.94% ± 4.58% and 10.53% ± 1.11% injected dose per gram at 0.5 and 24 h after injection, respectively. Greater than 82% of the injected radioactivity was cleared through the urinary system by 2 h after injection. The tumor-to-kidney uptake ratios reached 2.04 and 1.70 at 2 and 4 h after injection, respectively. Flank melanoma tumors were clearly visualized by SPECT/CT using 111In-DOTA-Nle-CycMSHhex as an imaging probe at 2 and 24 h after injection. The radioactivity accumulation in normal organs, except for the kidneys, was low at 2, 4, and 24 h after injection. Conclusion: The reduction of the peptide ring size dramatically increased the melanoma uptake and decreased the renal uptake of 111In-DOTA-Nle-CycMSHhex, providing a new insight into the design of a novel radiolabeled lactam bridge–cyclized α-MSH peptide for melanoma imaging and treatment.

14 February 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JYJianquan Yang
Jianquan Yang
JXJingli Xu
Jingli Xu
LCLina Cheuy
Lina Cheuy
RGRene Gonzalez
Rene Gonzalez
DFDarrell R. Fisher
Darrell R. Fisher
YMYubin Miao
Yubin Miao

1 April 2009 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
HGHaixun Guo
Haixun Guo
NSNalini Shenoy
Nalini Shenoy
BGBenjamin M. Gershman
Benjamin M. Gershman
JYJianquan Yang
Jianquan Yang
LSLarry A. Sklar
Larry A. Sklar
YMYubin Miao
Yubin Miao

24 June 2009 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
JYJianquan Yang
Jianquan Yang
HGHaixun Guo
Haixun Guo
FGFabio Gallazzi
Fabio Gallazzi
Marianne BerwickMarianne Berwick
Marianne Berwick
RPR. Steven Padilla
R. Steven Padilla
YMYubin Miao
Yubin Miao

1 November 2010 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
JYJianquan Yang
Jianquan Yang
HGHaixun Guo
Haixun Guo
YMYubin Miao
Yubin Miao